← Back
Data updated: Mar 10, 2026
SAMSUNG BIOEPIS CO LTD
ImmunologyGastroenterologyOncology
SAMSUNG BIOEPIS CO LTD is a biotechnology company focused on Immunology, Gastroenterology, Oncology.
2017
Since
11
Drugs
-
Trials
41
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
EPYSQLI 2026-01-23
REMS
ETICOVO 2025-12-05
Labeling
ONTRUZANT 2025-12-05
Labeling
EPYSQLI 2025-11-28
Efficacy
PYZCHIVA 2025-11-18
Labeling
PYZCHIVA 2025-11-18
Labeling
BYOOVIZ 2025-11-12
Labeling
EPYSQLI 2025-11-10
REMS
DENOSUMAB-DSSB 2025-10-29
Efficacy
RENFLEXIS 2025-10-28
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Immunology 31%
3 drugs Phase 3: 1 Phase 2: 2 Phase 1: 1
Gastroenterology 27%
4 drugs
Oncology 24%
2 drugs Phase 3: 2 Phase 1: 1
Ophthalmology 18%
1 drugs Phase 3: 2 Phase 2: 1
Pipeline Strength Pro
Loading...